Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug BW-50218 put to first safety test in healthy chinese volunteers

NCT ID NCT07577479

Knowledge-focused Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial is testing a single dose of an experimental drug called BW-50218 in 24 healthy Chinese adults. The main goal is to check for side effects and see how the drug moves through the body. Because it involves healthy participants, this study is not meant to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BW-50218
What could go wrong
This is an early-phase safety study in healthy people, so it cannot show whether BW-50218 works for any disease. The main risk is unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of providing written informed consent and complying with all study procedures for the duration of the study. * Body weight \> 50 kg for males and \> 45 kg for females; body mass index (BMI) within a range considered appropriate for study participation by the investigator. * Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception. * Male participants with partners of childbearing potential must agree to use effective contraception. Exclusion Criteria: * Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that, in the opinion of the Investigator, makes the participant unsuitable for participation in the study. * Recent hospitalization or a significant acute medical event. * History of cancer or any long-term medical condition that the study doctor considers clinically relevant. * Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1. * Positive test for hepatitis B, hepatitis C, or HIV.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants study are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants study

Contacts and locations

Locations

  • Argo Investigative Site

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.